WHO & Regional Offices [to 4 Dec 2021]

WHO & Regional Offices [to 4 Dec 2021]
Selected News, Statements
3 December 2021
Request for proposal: Technical support to SAGE executive secretariat

3 December 2021
Departmental news
South-East Asia: Influenza virus sharing in a time of COVID-19

3 December 2021
Departmental news
Global and regional support for the 2021–2022 influenza season

3 December 2021
Departmental news
Critical evidence to strengthen seasonal vaccination in the Americas

2 December 2021
Departmental news
Botswana is first country with severe HIV epidemic to reach key milestone in the elimination of mother-to-child HIV transmission

1 December 2021
Joint News Release
World AIDS Day 2021 – Step up, be bold, end AIDS, end inequalities and end pandemics

1 December 2021
Joint News Release
Tripartite and UNEP support OHHLEP’s definition of “One Health”

1 December 2021
News release
World Health Assembly agrees to launch process to develop historic global accord on pandemic prevention, preparedness and response

1 December 2021
Departmental news
It’s time for action on inequality to end TB and AIDS

30 November 2021
Departmental news
WHO Pandemic Ethics & Policy Summit

29 November 2021
Joint News Release
Joint Statement on Dose Donations of COVID-19 Vaccines to African Countries


Weekly Epidemiological Record, Vol. 96, No. 48, pp. 585–596 3 December 2021
:: Schistosomiasis and soil-transmitted helminthiases: progress report, 2020



WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Africa steps up Omicron variant detection as COVID-19 cases rise in southern Africa 02 December 2021
:: Botswana is first country with severe HIV epidemic to reach key milestone in the elimination of mother-to-child HIV transmission 02 December 2021
:: WHO stands with African nations and calls for borders to remain open 28 November 2021

WHO Region of the Americas PAHO
No new digest content identified

WHO South-East Asia Region SEARO
:: 1 December 2021 Statement- World AIDS Day
:: 27 November 2021 News release
WHO asks countries in South-East Asia Region to be vigilant as cases surge globally and new Variant of Concern is detected

WHO European Region EURO
:: What you need to know about the new Omicron COVID-19 variant 03-12-2021
:: Greece: civil society reduces barriers to health and education for young people with disabilities during the pandemic 03-12-2021
:: WHO/Europe high-level experts complete mission in Turkmenistan to strengthen health system preparedness 01-12-2021
:: Urgent need to take preventive measures in the fight against COVID-19 the focus of WHO/Europe advocacy campaign 30-11-2021
:: Building trust helps United Kingdom chart a path towards eliminating AIDS by 2030 30-11-2021

WHO Eastern Mediterranean Region EMRO
:: World AIDS Day: Reaching more people with HIV services and reducing inequalities 1 December 2021

WHO Western Pacific Region
:: 3 December 2021 Regional Director’s remarks at the virtual press conference on 3 December 2021



WHO Events
Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 7 December 2021
7 December 2021
This extraordinary virtual meeting for the Strategic Advisory Group of Experts on Immunization (SAGE) will take place on Tuesday 7 December 2021 to propose recommendations to WHO on the use of COVID-19 vaccine(s).
Agenda: https://cdn.who.int/media/docs/default-source/immunization/sage/2021/december/sage-agenda-7dect2021-virtual-draft-rev26nov.pdf?sfvrsn=f2b71e9f_10

Building stronger, sustainable, equitable societies for pandemic prevention and for navigating the response to the COVID-19 crisis
7 December 2021 12:00 – 13:00 CET
Join us to launch the new WHO evidence brief, “COVID-19 and the social determinants of health and health equity”, and to discuss the implications of the impacts of the social determinants of health equity for pandemic prevention, preparedness, response, and recovery.
* Tuesday 7 December 2021 * 12:00-13:00 Central European Time *
* Join via Zoom * https://who.zoom.us/j/96260096854
Password: Yt@W21bZ



New WHO Publications
Selected Titles
1 December 2021
Global vaccine safety blueprint 2.0 (‎GVSB2.0)‎ 2021-2023
This Global Vaccines Safety Blueprint 2.0 (GVSB2.0) was developed through a step-wise consensus process to define the strategic priorities and objectives in the area of vaccines safety for 2021 to 2023 and beyond. The overall vision, goals and operating principles for a vaccine safety monitoring system described in the GVSB2.0 are equally relevant for medicines and for building product-agnostic pharmacovigilance systems in countries. Where possible, we need to build common systems and approaches that are smart, product-agnostic, address common needs and advance the principles of work-sharing and reliance to take into consideration competing priorities in resource-limited settings. For example, how we collect and manage data (databases) may not be very different between vaccines and medicines; on the other hand, the principles of benefit risk assessment and how risks are communicated requires specialized and perceptive handling for vaccines.
PDF: https://apps.who.int/iris/rest/bitstreams/1392676/retrieve

1 December 2021
Global vaccine safety blueprint 2.0 background research

30 November 2021
Global progress report on WASH in health care facilities: Fundamentals first

30 November 2021
Framework for countries to achieve an integrated continuum of long-term care

30 November 2021
Approaches to enhance and accelerate study of new drugs for HIV and associated infections in pregnant…

29 November 2021
COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: ethical considerations
Executive Summary
In June 2020, global regulators convened under the auspices of the International Coalition of Medicines Regulatory Authorities (ICMRA) and co-chaired jointly by the European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) reached consensus on the study design requirements for Phase 3 COVID-19 vaccine clinical trials. The ICMRA noted that phase 3 clinical trials should be randomized, double-blinded and controlled with a placebo or active comparators. In September 2020, the World Health Organization (WHO ) advised: “Phase IIB/III efficacy trials should be randomized, double-blinded and placebo controlled.” Since then, multiple COVID-19 vaccines have been authorized worldwide based on interim results of pivotal placebo-controlled efficacy trials, and billions of COVID-19 vaccine doses have been administered under emergency use/conditional marketing authorization or full approval regulatory mechanisms.
In December 2020, a WHO expert group advised that the placebo control arms of COVID-19 vaccine trials should be progressively unblinded as authorized vaccines become available in the community hosting the trial, starting with prioritized groups.
Before a COVID-19 vaccine trial commences enrolment, if one or more authorized/approved COVID-19 vaccine is locally available and the participant meets programmatic eligibility criteria, the study team should advise the participant that they are eligible to receive the authorized vaccine(s). Participants may elect to receive the authorized vaccine at any point in the trial.
The appropriateness of conducting a placebo control trial may depend on whether the candidate vaccine is a prototype vaccine, modified vaccine or next generation vaccine
PDF: https://apps.who.int/iris/rest/bitstreams/1396234/retrieve

26 November 2021
Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus